Incorporated in October 2000, Molbio Diagnostics Limited is a healthcare technology company focused on developing and manufacturing point-of-care molecular diagnostic solutions. The company is best known for its proprietary Truenat platform, a portable, battery-operated PCR-based testing system that delivers accurate diagnostic results in less than an hour, making it well suited for hospitals, laboratories, and resource-constrained settings. 

Molbio offers diagnostic solutions for more than 30 diseases through 43 molecular test assays, covering tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, HPV, and several other infectious and non-communicable diseases. Beyond molecular diagnostics, the company has expanded into radiology, digital pathology, and breast health screening through strategic acquisitions and partnerships. Its strong in-house research and development capabilities continue to support the launch of new diagnostic products.

The company operates six manufacturing facilities in India and serves customers in over 90 countries, including government healthcare programs, hospitals, diagnostic laboratories, and international health organizations. As of March 31, 2026, Molbio Diagnostics had a workforce of 1,225 employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.